

CHAIRMAN'S STATEMENT

.....

To the shareholders,

Dear Sir or Madam,

In the past few years, our business was hindered by heavy indebtedness. We had and were forced to dispose of most of our assets and part of our business to reduce this burden of indebtedness. Much efforts and resources were devoted to debt restructuring and very less was spent on business development.

However, in 2005 the situation changed. When you read the financial statements, you may find the Group's turnover increased, its assets size enlarged and most importantly was that the Group regained momentum in its business operation.

Based on the performance of Tianjin Jinshun Pharmaceutical Co., Ltd. in the past few months, we are optimistic that this Sino-foreign joint venture, a 60% owned subsidiary of the Company engaging in pharmaceutical distribution business will contribute a lot to the Group's income and results in 2006. GenePro Medical Biotechnology Ltd, a wholly owned subsidiary of the Company specializing in R&D and service in nucleic acid diagnostics, with the advantage of its less costly in-house-developed versions of tests will continue to grow steadily. Following the launching of its products, its income and profit will increase substantially.

While the trading of the Company's shares remain suspended, we believe that if we follow our business model and direction in pharmaceutical/healthcare and properties, our operation level and assets size will warrant the Company to resume trading of its shares in the near future.

Lastly, we would like to sincerely thank our customers, shareholders and staff for their understanding and support to the Company.

Yours sincerely,

Wu Kwai Yung

Chairman

Hong Kong, 21 April 2006